Introduction
Cancer treatment has advanced dramatically, encompassing diverse strategies such as surgery, chemotherapy, radiation therapy, targeted therapies including antibody-drug conjugates (ADCs), and the rapidly growing field of immuno-oncology (IO). IO therapies—such as immune checkpoint inhibitors, T cell engagers, CAR-T cell therapy, and cancer vaccines—are transforming oncology by harnessing the body's immune system to recognize and eliminate tumors. The successful development of these innovative treatments relies heavily on preclinical evaluation using robust and translational animal models.
Biocytogen has established a comprehensive portfolio of oncology and immuno-oncology models to evaluate novel cancer therapeutics and combination strategies. These include syngeneic mouse models, particularly those based on gene humanized mice, which maintain fully functional immune systems for accurate assessment of immune-mediated anti-tumor responses. In addition, Biocytogen offers xenograft models using immunodeficient mice and orthotopic tumor models to replicate clinically relevant tumor microenvironments.
To further enhance research capabilities, Biocytogen has developed luciferase-labeled tumor cell lines that enable in vivo imaging and real-time tumor monitoring in both syngeneic models and xenograft model settings. Supported by an experienced pharmacology team, we provide integrated in vivo efficacy studies, ex vivo pharmacodynamic (PD) and pharmacokinetic (PK) analyses, and in vitro assays—offering end-to-end support for clients' preclinical oncology research and IND-enabling studies.
